Eurofins’ GLP 1 agonist multiplex testing enables rapid, data-driven decision-making and improves success rates in treating complex diseases
Paul Morrissey, PhD, Senior Manager, Molecular & Cell Biology, Eurofins BioPharma Product Testing Ireland, paul.morrissey@bpt.eurofinseu.com; Devakumar Sundaravinayagam, PhD, Senior Scientist, Biopharm, Devakumar.Sundaravinayagam@bpt.eurofinseu.com
With the rapid expansion of GLP 1 receptor agonists in the treatment of obesity, type 2 diabetes, and metabolic disorders, the demand for high-sensitivity, high-throughput bioanalytical platforms has never been greater. At Eurofins BioPharma Product Testing (BPT) Dungarvan, we have invested in the MESO QuickPlex® SQ 120MM, a state of the art electrochemiluminescence (ECL) detection system, to deliver fast, precise, and regulatory compliant testing for our global client base.
Why the MESO QuickPlex® SQ 120MM?
The MESO QuickPlex platform offers unmatched analytical performance for ligand binding assays and immunogenicity testing, making it ideal for the potency, pharmacokinetic (PK), and biomarker analysis of GLP 1 agonists. Its unique ECL technology provides:
- Ultra low detection limits with low sample volume
- Multiplexing capability with low turnaround time
- Exceptional reproducibility
- Wide dynamic range
Applications in GLP 1 agonist development
Our Dungarvan team leverages the MESO QuickPlex SQ 120MM for:
- Potency assays aligned with GLP 1 receptor pharmacology
- Simultaneous quantitation of multiple analytes within a single well, using U-Plex and V-Plex multiplexing platforms
This capability supports the development of multi-target therapies by enabling rapid, data-driven decision-making across both preclinical and clinical stages. It facilitates efficient candidate selection, dosing optimisation, and enhances translational predictability. Additionally, it contributes to mechanism-of-action research and adaptive trial design, ultimately improving development efficiency and success rates in treating complex diseases such as metabolic disorders.
Multiplexing strategy using U-PLEX and V-PLEX platforms
Multiplexing is a powerful analytical technique that enables the simultaneous quantitation of multiple analytes within a single well. This approach significantly enhances efficiency by reducing the number of plates required for analysis and conserving valuable sample volume, allowing up to 10 different analytes to be measured from just 20 μL of sample.
At the Eurofins BPT’s Dungarvan site, we are adopting U-PLEX multiplexing technology to customise assay plates and optimise experimental conditions tailored to our specific analytical needs. Following this, we can validate to V-plex level, resulting in a validated kit-based assay that offers enhanced robustness and reproducibility for routine testing.
This strategic approach is expected to streamline our workflows, improve data quality, and support high-throughput analysis in a cost-effective manner.
Partnering for Success
Whether you are advancing a first in human GLP 1 analogue or optimising a late stage clinical candidate, the MESO Quick-Plex SQ 120MM at Eurofins BPT Dungarvan offers the precision, speed, and compliance to accelerate client programs.
Contact us at: EurofinsBPT-IE@bpt.eurofinseu.com or visit our website here: www.eurofins.ie/biopharma-product-testing-ireland/